Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016

Publisher Name :
Date: 01-Oct-2016
No. of pages: 1000
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2010 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.

Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.

Chapter 5 provides a review of clinical stage deal making since 2010. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.

Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2010 organized by stage of development - phase I, phase II and phase III.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2010.

In addition, a comprehensive appendix of all clinical stage deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.

Key benefits

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 provides the reader with the following key benefits:

In-depth understanding of clinical stage deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of clinical stage agreements with numerous real life case studies

Insight into the terms included in a clinical stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 includes:

Trends in clinical stage dealmaking in the biopharma industry since 2010

Analysis of clinical stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life clinical stage deals

Access to over 2,000 clinical stage deals

The leading clinical stage deals by value since 2010

Most active clinical stage dealmakers since 2010

The leading clinical stage partnering resources

In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 report provides comprehensive access to available deals and contract documents for over 2,000 clinical stage deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?
2.1. Introduction
2.2. The role of clinical stage partnering
2.2.1. In-licensing at clinical stage
2.2.2. Out-licensing at clinical stage
2.3. Difference between phase I, II and III stage deals
2.4. Reasons for entering into clinical stage partnering deals
2.4.1. Licensors reasons for entering clinical stage deals
2.4.2. Licensees reasons for entering clinical stage deals
2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Argos Therapeutics - Medinet
3.6.1.b. Case study : Pfizer - GlycoMimetics
3.7. Multicomponent clinical stage partnering agreements
3.7.1. Example multicomponent clinical stage clauses
3.7.1.a. Case study: Gilead Sciences - GlobeImmune

Chapter 4 - Clinical stage partnering payment strategies
4.1. Introduction
4.2. Clinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making
5.1. Introduction
5.2. Clinical stage partnering over the years
5.2.1. Trends in phase I deals since 2010
5.2.1.1. Attributes of phase I deals
5.2.2. Trends in phase II deals since 2010
5.2.2.2. Attributes of phase II deals
5.2.3. Trends in phase III deals since 2010
5.2.3.1. Attributes of phase III deals
5.3. Clinical stage partnering by deal type
5.4. Clinical stage partnering by disease type
5.5. Partnering by clinical stage technology type
5.6. Clinical stage partnering by most active company, 2010 to 2016

Chapter 6 - Payment terms for clinical stage partnering
6.1. Introduction
6.2. Guidelines for clinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Clinical stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Clinical stage partnering headline values
6.4.2. Clinical stage deal upfront payments
6.4.3. Clinical stage deal milestone payments
6.4.4. Clinical stage royalty rates
6.5 Clinical stage median financials
6.5.1. Clinical stage headline value
6.5.2. Clinical stage upfront value
6.5.3. Clinical stage milestone value
6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals
7.1. Introduction
7.2. Top clinical stage deals by value

Chapter 8 - Top 50 most active clinical stage dealmakers
8.1. Introduction
8.2. Top 50 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory
9.1. Introduction
9.2. Clinical stage deals with contracts 2010 to 2016

Chapter 10 - Clinical stage deal making by development stage
10.1. Introduction
10.2. Deals by clinical stage
Phase I
Phase II
Phase III
Regulatory
Formulation

Appendices
Appendix 1 - Clinical stage dealmaking by companies A-Z
Appendix 2 - Clinical stage dealmaking by industry sector
Appendix 3 - Clinical stage dealmaking by stage of development
Appendix 4 - Clinical stage dealmaking by therapy area
Appendix 5 - Clinical stage dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Definition of clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2010- 2016), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for clinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Clinical stage partnering frequency 2010- 2016
Figure 7: Phase I clinical stage partnering since 2010
Figure 8: Phase II clinical stage partnering since 2010
Figure 9: Phase III clinical stage partnering since 2010
Figure 10: Clinical stage partnering by deal type since 2010
Figure 11: Clinical stage partnering by disease type since 2010 80
Figure 12: Clinical stage partnering by technology type since 2010
Figure 13: Top 50 most active clinical stage dealmakers, 2010 to 2016
Figure 14: Review of upfront payments for clinical stage deals
Figure 15: Review of milestone payments for clinical stage deals
Figure 16: Review of royalty payments for clinical stage deals
Figure 17: Clinical stage deals with a headline value
Figure 18: Clinical stage deals with an upfront value
Figure 19: Clinical stage deals with a milestone value
Figure 20: Clinical stage deals with a royalty rate value
Figure 21: Summary median headline value by clinical stage of development, 2010-2016
Figure 22: Summary median upfront payments by clinical stage of development, 2010-2016
Figure 23: Summary median milestone payments by stage of development, 2010-2016
Figure 24: Summary median royalty rate by stage of development, 2010-2016
Figure 25: Top clinical stage deals by value since 2010
Figure 26: Most active clinical stage dealmakers 2010 to 2016
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new [...]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating [...]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global High-Throughput Screening Market Research Report 2016
    Published: 04-Jan-2017        Price: US 2900 Onwards        Pages: 109
    Notes: Production, means the output of High-Throughput Screening Revenue, means the sales value of High-Throughput Screening This report studies High-Throughput Screening in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Agilent Technologies, Inc. (U.S.) - Danaher Corporation (U.S.......
  • Sareum Holdings Plc - Product Pipeline Review - 2016
    Published: 30-Dec-2016        Price: US 1500 Onwards        Pages: 37
    Sareum Holdings Plc - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Sareum Holdings Plc - Product Pipeline Review - 2016', provides an overview of the Sareum Holdings Plc's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sareum Holdings Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administrati......
  • Phylogica Ltd - Product Pipeline Review - 2016
    Published: 30-Dec-2016        Price: US 1500 Onwards        Pages: 29
    Phylogica Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Phylogica Ltd - Product Pipeline Review - 2016', provides an overview of the Phylogica Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Phylogica Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule ty......
  • Polyphor Ltd - Product Pipeline Review - 2016
    Published: 21-Dec-2016        Price: US 1500 Onwards        Pages: 39
    Polyphor Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Polyphor Ltd - Product Pipeline Review - 2016', provides an overview of the Polyphor Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Polyphor Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also c......
  • Europe High Content Screening Market Report to 2021
    Published: 14-Oct-2016        Price: US 3900 Onwards        Pages: 124
    Notes: Sales, means the sales volume of High Content Screening Revenue, means the sales value of High Content Screening This report studies sales (consumption) of High Content Screening in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Thermo Fisher Scientific (U.S.) - Molecular Device......
  • Europe High Throughput Screening (HTS) Market Report to 2021
    Published: 14-Oct-2016        Price: US 3900 Onwards        Pages: 121
    Notes: Sales, means the sales volume of High Throughput Screening (HTS) Revenue, means the sales value of High Throughput Screening (HTS) This report studies sales (consumption) of High Throughput Screening (HTS) in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Agilent Technologies, Inc. (U.......
  • United States High Throughput Screening (HTS) Market Report to 2021
    Published: 13-Oct-2016        Price: US 3800 Onwards        Pages: 120
    Notes: Sales, means the sales volume of High Throughput Screening (HTS) Revenue, means the sales value of High Throughput Screening (HTS) This report studies sales (consumption) of High Throughput Screening (HTS) in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Agilent Technologies, Inc. (U.S.) - PerkinElmer (U.S.) - Beckman Coulter, Inc. (a subsidiary of Danaher Corporat......
  • United States High Content Screening Market Report to 2021
    Published: 13-Oct-2016        Price: US 3800 Onwards        Pages: 122
    Notes: Sales, means the sales volume of High Content Screening Revenue, means the sales value of High Content Screening This report studies sales (consumption) of High Content Screening in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Thermo Fisher Scientific (U.S.) - Molecular Devices (U.S.) - Perkin Elmer (U.S.) - GE Healthcare Lifesciences (U.K - ?Merck M......
  • SciFluor Life Sciences, LLC - Product Pipeline Review - 2016
    Published: 12-Oct-2016        Price: US 1500 Onwards        Pages: 32
    Global Markets Direct's, ‘SciFluor Life Sciences, LLC - Product Pipeline Review - 2016', provides an overview of the SciFluor Life Sciences, LLC's pharmaceutical research and development focus.The report provides comprehensive information on the therapeutics under development by SciFluor Life Sciences, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacologi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs